Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
← catalyst calendarNCT06846541 · readout ≤ 834 d
Sponsored by Alumis Inc (industry) · ALMS — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,680estimated
Sites
268
Countries
Australia, Bulgaria, Canada +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-08 | actual | When the study began enrolling |
| Primary completion | Nov 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Plaque Psoriasis
- Psoriasis (PsO)
- Psoriasis
- Moderate Psoriasis
- Severe Psoriasis
Interventions
- Drug: Open-Label Envudeucitinib
- Drug: Blinded Envudeucitinib
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTo assess the long-term safety and tolerability of ESK-001 throughout the duration of the study
measured Approximately 4 years
Permalink · ALMS's whole pipeline · Catalyst calendar · Every registered study · What changed